Yesterday, the CSO of Applied Genetic Technologies (AGTC), Mark Shearman, sold shares of AGTC for $10.05K.
In addition to Mark Shearman, 2 other AGTC executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Applied Genetic Technologies’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $14.03 million and quarterly net profit of $1.2 million. In comparison, last year the company earned revenue of $10.32 million and had a GAAP net loss of $1.4 million. Currently, Applied Genetic Technologies has an average volume of 299.4K.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $6.94, reflecting a 146.1% upside.
In the last 30 days, insiders have sold $10.05K worth of AGTC shares and purchased $17.94K worth of AGTC shares.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology.
